Results 201 to 210 of about 118,457 (381)

Transcatheter Left Ventricular Restoration in Ischemic Heart Failure and Dilated Cardiomyopathy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Ischemic heart disease is the leading global cause of death and frequently progresses to ischemic heart failure (IHF) after myocardial infarction through adverse left ventricular (LV)remodeling. Surgical LV restoration improves ventricular geometry and function but is limited by invasiveness and inconsistent outcomes.
Muhammad Mohid Haroon, Faizan Ahmad, Ramsha Ali, Saqlain Haider, Areehah Zafar Masood, Usama Yaseen, Taha Ahmad Zaka Ur Rehman, Muhammad Abdullah Sardar, Muhammad Umer, Shruthi Aswathappa, Muhammad Salman Sabri, Muhammad Muneeb Murtaza, Rubiya Ali, Sunny Kumar, Sameer Ali, Najam Gohar, Mohamed Bakr, Swapnil Patel, Mohammad A. Hussain, Fawaz Alenezi   +19 more
wiley   +1 more source

Elevated Hemoglobin Levels and Risk of ST‐Segment Elevation Myocardial Infarction in High‐Altitude Acute Coronary Syndrome: A Retrospective Analysis

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background High‐altitude populations typically exhibit elevated hemoglobin (Hb) levels due to chronic hypoxic exposure; however, the impact of this elevation on the risk of ST‐segment elevation myocardial infarction (STEMI) remains unclear. Existing evidence is primarily derived from low‐altitude populations and cannot be directly extrapolated
Jing Li, Lin‐Feng Liu, Gusang Lamu, Yang Jin, Gesang Gawa, Zhen‐Long Chang, Xiao‐Xia Liu, Zhen‐Zhong Yang, Gesang Luobu, Baima Lamu, Dawa Ciren   +10 more
wiley   +1 more source

In-Silico assessment of aortic valve function and mechanics under hypertension. [PDF]

Front Cardiovasc Med
Shar JA, Sucosky P.
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Right Ventricular Myocardial Strain and Proteomic Analysis of Fetuses With Left Ventricular Hypoplasia: A Cross-Sectional Study. [PDF]

Health Sci Rep
Ma J, Xiao S, Hong L, Liu J, Jiawei S, Zhang Y, Cui L, Cao H, Xie M, Zhang L.   +9 more
europepmc   +1 more source

Corrigendum to “Patient-specific in vivo right ventricle material parameter estimation for patients with tetralogy of fallot using MRI-Based models with different zero-load diastole and systole morphologies” [Int. J. Cardiol. 276 (2019) 93–99] [PDF]

, 2019
Han Yu, Pedro J. del Nido, Tal Geva, Chun Yang, Alexander Tang, Zheyang Wu, Rahul H. Rathod, Xueying Huang, Kristen L. Billiar, Dalin Tang   +9 more
openalex   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome. [PDF]

J Pharm Pharm Sci
Shafaati T, Greenwell AA, Saed CT, Tabatabaei Dakhili SA, Chan JSF, Dong L, Stenlund MJ, Ferrari SR, Han R, Kruger J, Eaton F, Gopal K, Davidge ST, Oudit GY, Ussher JR.   +14 more
europepmc   +1 more source

Volume at End Ventricular Diastole [PDF]

, 2020
National Cancer Institute
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source